COL18A1 Protein

Produktnummer ABIN621729

Produktdetails

Target: COL18A1 (Collagen, Type XVIII, alpha 1 (COL18A1))

Protein-Typ: Recombinant

Spezies: Human

Wirt: Bitte anfragen

Sequenz: In total agreement with the expected amino acid compositio n of native human Endostatin

Produktmerkmale: Recombinant Human Endostatin

Reinheit: > 98.0 % as determined by (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: The recombinant Human Endostatin is formulated with PBS.

Lagerung: -20 °C

Antigendetails

Target: COL18A1 (Collagen, Type XVIII, alpha 1 (COL18A1))

Andere Bezeichnung: Endostatin (COL18A1 Produkte)

Synonyme: KNO Protein, KNO1 Protein, KS Protein, cb371 Protein, cb529 Protein, fc96d06 Protein, sb:cb529 Protein, wu:fb47h10 Protein, wu:fb77g12 Protein, wu:fc50f04 Protein, wu:fc96d06 Protein, wu:fk02h12 Protein, kno Protein, kno1 Protein, collagen type XVIII alpha 1 chain Protein, collagen type XVIII alpha 1 chain a Protein, collagen, type XVIII, alpha 1 Protein, collagen type XVIII alpha 1 Protein, COL18A1 Protein, col18a1a Protein, Col18a1 Protein, col18a1 Protein

Substanzklasse: Chemical

Hintergrund: Endostatin Human Recombinant produced in Pichia Pastoris is a single, glycosylated, polypeptide having a total molecular mass of 20,000 Dalton C-terminal fragment of collagen XVIII that has been shown to act as a potent inhibitor of angiogenesis and tumor growth in vitro and in vivo. Induces tyrosine phosphorylation of Shc (SH2 domain adapter protein) leading to specific inhibition in endothelial cell proliferation. The Endostatin is purified by proprietary chromatographic techniques. Introduction: Once a cluster of cancer cells reaches a diameter of about 1“2 mm, it must develop a blood supply in order to grow larger. Given that diffusion is no longer adequate to supply the cancerous cells with oxygen and nutrients and to remove wastes. Therefore, these cells secrete substances that promote the formation of new blood vessels (angiogenesis), which are vital for the growth and persistence of solid tumors and their metastases. The production of several angiogenic factors (FGF-a, FGF-b, VEGF and VPF) is upregulated by tumors in order to stimulate angiogenesis. However, numerous malignant tumors also generate inhibitors of angiogenesis which include angiostatin and thrombospondin. The angiogenic phenotype is basically the end result of a net balance between the positive and negative regulators of neovascularization mentioned above. Endostatins role is to inhibit endothelial proliferation, therefore it is an effective angiogenesis inhibitor.